NGM282 — an engineered analogue of FGF19 — shows promise in patients with primary sclerosing cholangitis
13 April 2018, Paris, France: The fibroblast growth factor 19 (FGF19) engineered analogue, NGM282, inhibits bile acid synthesis, decreases markers of hepatic inflammation, and significantly...